Switch View
© Newsfile
02.10.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group Enters into Definitive Agreement in Respect of Call Option to Purchase Remaining 50% of Heal Wellness
News Preview
Toronto, Ontario--(Newsfile Corp. - October 2, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands, is pleased to announce that it has entered into a definitive share purchase agreement effective as of October 9, 2025 (the "SPA"), and currently held...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
News Preview
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently w...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against LifeMD, Inc. ("LifeMD" or "the Company") (NASDAQ: LFMD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
02.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NUTX
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nutex Health Inc. ("Nutex " or "the Company") (NASDAQ: NUTX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities a...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
02.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SMLR
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler " or "the Company") (NASDAQ: SMLR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securi...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Investors Have Opportunity to Lead Semler Scientific, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ: SMLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the Company") (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulg...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Ex...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus " or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secu...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of the securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics ("MoonLake" or "the Company") (NASDAQ: MLTX) for violations of the securities laws.
INVESTIGATION DETAILS: The investigatio...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
02.10.2025
ISIN: US45773H4092
Inovio Pharmaceuticals Inc
INO
LISTED
NASDAQ
INOVIO Reports Inducement Grant Under Inducement Plan
News Preview
PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired em...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US4364401012
Hologic Inc
HOLX
LISTED
NASDAQ
Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis
News Preview
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Panther Fusion® Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays. The company also announced that the assays obtained CE marking in the European Union in accordance with In Vitro Diagnostic Regulation (IVD...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US28036F1057
Edgewise Therapeutics Inc
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society
News Preview
BOULDER, Colo., Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS). Importantly, the presentations will include a compilation of...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie to Host Third-Quarter 2025 Earnings Conference Call
News Preview
NORTH CHICAGO, Ill., Oct. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: GG00BMF1JR16
Genius Sports Limited
GENI
LISTED
NYSE
Genius Sports Announces Change of Auditor
News Preview
Genius Sports Limited (NYSE:GENI) (“Genius Sports”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced that it intends to change its independent auditor from WithumSmith+Brown, PC ("Withum") to KPMG LLP ("KPMG") after the completion of Withum’s audit of the fi...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
News Preview
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has begun opening clinical trial sites in the European Union (EU) and may begin screening participants for the Phase 3 ALPHA-ORBIT trial of navenibart, an investigational...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US7140461093
Revvity Inc
RVTY
LISTED
NYSE
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
News Preview
Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.
T1D is...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: CA71719L1067
Pharmala Biotech Holdings Inc.
MDMA
LISTED
CSE
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
News Preview
PharmAla completes first domestic US shipment of MDMA from its new domestic distribution center, and issues shares as debt payment....
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: IT0004147952
Newron Pharmaceuticals SpA
NWRN
LISTED
SIX
Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that it will present three posters at the upcoming 38th Congress of the European College of Neuropsychopharmacology taking pla...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US4834971032
Kalvista Pharmaceuticals Inc
KALV
LISTED
NASDAQ
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors
News Preview
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig’s appointment to the Audit Committee, Nancy Stuart will transition off the Aud...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US7133171055
PepGen Inc
PEPG
LISTED
NASDAQ
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
News Preview
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company’s data will be presented in two oral presentations at the 30th Annual International Congress of...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
Daiichi Sankyo Establishes Third Research Institute in San Diego
News Preview
Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside of the company’s flagship research center in Japan since the opening of locations in Boston and Munich in 2024.
“Establishing a dedicated scientific presence in San Diego marks a significant mil...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US1124631045
Brookdale Senior Living Inc
BKD
LISTED
NYSE
Brookdale Appoints Nick Stengle as CEO
News Preview
Proven Executive Brings Extensive Experience in Senior Living, Healthcare, and Hospitality and Track Record of Driving Durable, Sustainable Operational Excellence
NASHVILLE, Tenn., Oct. 2, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: CA82621K1021
Sienna Senior Living Inc
SIA
LISTED
TSX
Sienna Senior Living Completes Acquisition in Greater Toronto Area
News Preview
MARKHAM, Ontario, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX: SIA) announced today that it has finalized its acquisition of Cawthra Gardens, a 192-bed Class A long-term care home in Mississauga, Ontario, for a gross purchase price of $32.6 million, including a $2.0 million capital allowance that t...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US24906P1093
DENTSPLY SIRONA Inc
XRAY
LISTED
NASDAQ
Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization
News Preview
CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company’s focus on the customer by alig...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US1255091092
Cigna Group (The)
CI
LISTED
NYSE
The Cigna Group's Third Quarter 2025 Earnings Release Details
News Preview
BLOOMFIELD, Conn., Oct. 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2025 financial results on Thursday, October 30, 2025, and will host a conference call the same day....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US8776191061
Taysha Gene Therapies Inc
TSHA
LISTED
NASDAQ
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
News Preview
Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US2528281080
Dianthus Therapeutics Inc
DNTH
LISTED
NASDAQ
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
News Preview
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized Myasthenia Gravis Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US01625V1044
Alignment Healthcare Inc
ALHC
LISTED
NASDAQ
Alignment Healthcare to Announce Third Quarter 2025 Financial Results and Host Conference Call Thursday, Oct. 30, 2025
News Preview
ORANGE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2025 financial results on Thursday, Oct. 30, 2025, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EDT....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
News Preview
BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportun...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: IL0011407140
Urogen Pharma Ltd
URGN
LISTED
NASDAQ
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
News Preview
Reviews in Urology literature review of ZUSDURI (UNG-102) clinical trial program including ENVISION, OPTIMA II and the ATLAS clinical trials...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US03475V1017
AngioDynamics Inc
ANGO
LISTED
NASDAQ
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
News Preview
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US0327973006
Anavex Life Sciences Corp
AVXL
LISTED
NASDAQ
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
News Preview
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US0327973006
Anavex Life Sciences Corp
AVXL
LISTED
NASDAQ
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
News Preview
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US67577C1053
Ocugen Inc
OCGN
LISTED
NASDAQ
Ocugen to Present at Industry and Investor Conferences in October 2025
News Preview
MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan’s 9th Annual Genetic Medicines Conference, and the 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US17166A1016
Cibus Inc
CBUS
LISTED
NASDAQ
Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola
News Preview
Field testing confirms efficacy of HT2 trait in Canola under real-world conditions...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
News Preview
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rare, rapidly progressing, neurodegenerative disease with n...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: US70805E1091
Pennant Group Inc
PNTG
LISTED
NASDAQ
Pennant Completes Purchase of Tennessee, Georgia and Alabama Operations from UnitedHealth Group and Amedisys
News Preview
EAGLE, Idaho, Oct. 02, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that on October 1, 2025, it acquired certain operations from UnitedHealth Group Incorporated (“UnitedHealth”). The operations wer...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: AU000000IMC7
Immuron Limited
IMC
LISTED
ASX
Immuron Letter to Shareholders – Projects Update
News Preview
Highlights:...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
News Preview
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rare, rapidly progressing, neurodegenerative disease with n...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
News Preview
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 20251-3
MSA is a rare, rapidly progressing, neurodegenerative disease with n...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.10.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Correction - Genflow Biosciences PLC Announces Issue of Equity
News Preview
The following amendment has been made to the 'Subscription of New Ordinary Shares, Warrant Issue, PDMR Dealings' announcement released on 01 October 2025.The sentence "being the bid price as at close of business on 1 October 2025" has been corrected to "being a 35% discount to the bid price as at close of business on 1 October 2025.&...
Themefolio
Profiler
Peergroup
© Newsfile
02.10.2025
ISIN: CA24463V1013
Defence Therapeutics Inc.
DTC
LISTED
CSE
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
News Preview
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings ove...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.10.2025
ISIN: US2498451085
Dermata Therapeutics Inc
DRMA
LISTED
NASDAQ
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
News Preview
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC) pharmaceutical acne kit, incorporating its Spongilla technology, in the middle of 2026 -- Over 3.3 million people are diagnosed with acne in...
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: IT0004147952
Newron Pharmaceuticals SpA
NWRN
LISTED
SIX
Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
News Preview
Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025
New post-hoc analyses highlighting the clinical benefit of evenamide for patients with treatment-resistant schizophrenia (TRS) or those in......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: IT0004147952
Newron Pharmaceuticals SpA
NWRN
LISTED
SIX
Newron präsentiert neue Analysen und Updates zu seinem klinischen Programm zur Bewertung von Evenamide als Zusatztherapie bei Schizophrenie auf dem 38. Kongress des ECNP 2025
News Preview
Newron präsentiert neue Analysen und Updates zu seinem klinischen Programm zur Bewertung von Evenamide als Zusatztherapie bei Schizophrenie auf dem 38. Kongress des European College of Neuropsychopharmacology (ECNP) 2025
Neue Post-hoc-Analysen bestätigen den klinischen Nutzen von Evenamide für Patienten mit behandlungsresistenter Schizophrenie (tr......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron
News Preview
Pressemitteilung // 2. Oktober 2025
Formycon sichert US-Vermarktungsstart für Aflibercept-Biosimilar FYB203 durch Settlement-Vereinbarung mit Regeneron
Formycon und seine Partner haben mit Regeneron eine Vergleichs- und Lizenzvereinbarung für FYB203/AHZANTIVE®1 (Aflibercept-mrbb) abgeschlossen
Die anhängigen Verfahren vor dem US-Bezirksgericht ......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.10.2025
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
News Preview
Press Release // October 2, 2025
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE® (Aflibercept-mrbb)
Pending litigation at the U.S. District Court fo......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.10.2025
ISIN: US63633D1046
National Health Investors Inc
NHI
LISTED
NYSE
NHI Announces $74.3 Million SHOP Investment
News Preview
MURFREESBORO, TN / ACCESS Newswire / October 2, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it has invested $74.3 million, including transaction costs, for the acquisition of four properties with 344 units in Oklahoma and Oregon. The properties and healthcare operations will be included in NHI's Senior Housing Operating P...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.10.2025
ISIN: GB00BP2C3V08
Genflow Biosciences Plc
GENF
LISTED
LSE
Genflow Biosciences PLC Announces Issue of Equity
News Preview
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SE...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
SMLR Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Securities Fraud Class Action Against Semler Scientific, Inc.
News Preview
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Semler Scientific, Inc. (NASDAQ: SMLR) securities between March 10, 2021 and April 15, 2025. Semler Scientific describes itself as a company...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.10.2025
ISIN: CA98421R1055
XPhyto Therapeutics Corp.
XPHY
LISTED
CSE
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
News Preview
VANCOUVER, BC, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage biopharmaceutical company specializing in advanced drug-delivery technologies, is pleased to report a significant advancement regarding its targeted chemotherapy delivery...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2025
ISIN: US81684M1045
Semler Scientific Inc
SMLR
LISTED
NASDAQ
Semler Scientific, Inc. INVESTOR ALERT: Kirby McInerney LLP Notifies Semler Scientific, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
News Preview
Kirby McInerney LLP reminds Semler Scientific, Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) investors of the October 28, 2025 deadline to seek the role of lead plaintiff in a pending federal securities class action.
If you purchased or otherwise acquired Semler Scientific securities, have information, or would like to learn more, please contac...
Themefolio
Profiler
Peergroup
© PR Newswire
02.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 1, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDA...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2025, taking place on...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ISIN: US26622P1075
Doximity Inc
DOCS
LISTED
NYSE
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
News Preview
Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.
Investors who have continuously held Doximity shares since before June 24, 2021, may have legal rights and are enco...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
News Preview
NEW YORK, Oct. 1, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
